In Vitro Diagnostics: Buy-Side M&A Strategies & Trends

This article is one in a series covering trends in healthcare & medical M&A transactions, including opportunities and trends in the large and growing diagnostics sector. The In-Vitro Diagnostics (IVD) market experienced heavy investment and a hot transaction market in 2016. With a few blockbuster M&A deals, 2016 surpassed the record-breaking year of 2011 with the highest amount of capital invested in the industry’s history. In 2016, there was just over $13B in disclosed transactions, compared to 2011’s $11.76B.[i] Despite varying amounts of invested capital over the past seven years, deal flow has seen consistent and growth has been strong. Growing at a CAGR of 10.6%, deal flow has grown from 174 total deals in 2011 to 319 in 2016.[ii] Why is the IVD industry an attractive buy-side opportunity? The IVD market is attractive because of its stability, size, and growth. Large, Stable Industry With a 2017 revenue of close to $64B, and projected 5-year growth…

Read more detail on Recent Banking and Finance Law posts –

This entry was posted in Banking and Finance law and tagged , , , , , , . Bookmark the permalink.

Leave a Reply